|Awarded On||December 05, 2012|
|Title||Imaging cancerous tissues with liposomal MRI contrast agents that utilize bioengineered nanovalves|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||Paul Blount|
|Cancer Sites||All Sites|
One cannot overemphasize the importance of early detection of cancerous tumors. The earlier a cancer can be detected, the more likely it can be eradicated by conventional surgery or other therapies. One of the most used methods for detecting such tumors is magnetic resonance imaging, or MRI. To better distinguish normal and cancerous tissues, a contrast agent is usually injected into the patient. However, most clinically approved contrast agents are non specific for cancerous tissues. Our proposal is aimed at designing a “responsive” or “smart” contrast agent. Briefly, we are making a nanodevice by combining biological and chemical components that will not only have a tendency to localize wi...